PPBT Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

1.590

Open

1.590

VWAP

1.56

Vol

16.04K

Mkt Cap

1.48M

Low

1.550

Amount

25.07K

EV/EBITDA(TTM)

--

Total Shares

932.27K

EV

4.52M

EV/OCF(TTM)

--

P/S(TTM)

--

Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.

Show More

Events Timeline

(ET)

2026-06-11

08:30:00

Purple Biotech Presents New IM1240 Data at EACR 2026

2026-05-20 (ET)

2026-05-20

17:40:00

Purple Biotech Files $200M Mixed Securities Shelf

2026-04-27 (ET)

2026-04-27

07:40:00

Purple Biotech Announces New Preclinical Data for IM1240

2026-03-25 (ET)

2026-03-25

08:20:00

Purple Biotech Collaborates with Converge Bio to Enhance Antibody Platform

2026-03-13 (ET)

2026-03-13

08:10:00

Purple Biotech CEO Gil Efron to Step Down in August 2026

2026-03-13

08:10:00

Purple Biotech Plans to Strengthen IM1240 Research in 2025

2026-02-27 (ET)

2026-02-27

19:50:00

Purple Biotech Trading Halted, News Pending

2026-02-25 (ET)

2026-02-25

17:40:00

Purple Biotech Adjusts ADS Ratio to 1:2000

News

Newsfilter

06-11Newsfilter

Purple Biotech's IM1240 Study Advances with Promising Results

seekingalpha

05-15seekingalpha

Purple Biotech Reports Q1 2026 Financial Results

moomoo

PURPLE BIOTECH LTD FORMS SCIENTIFIC ADVISORY BOARD FOR CAPTN-3 ANTIBODY PLATFORM

moomoo

Purple Biotech Partners with Converge Bio to Enhance Development of Next-Generation Tri-Specific Antibody Platform Using AI

seekingalpha

03-17seekingalpha

Purple Biotech Regains Nasdaq Compliance

seekingalpha

03-13seekingalpha

Purple Biotech Reports Q4 Non-GAAP EPS of $19.85 Amid Increased Losses

1 Analyst Rating

Wall Street analysts forecast PPBT stock price to rise

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

34.00

Averages

34.00

High

34.00

Current: 0.000

Low

34.00

Averages

34.00

High

34.00

H.C. Wainwright

Emily Bodnar

Buy

downgrade

$34 -> $30

AI Analysis

2026-03-13

Reason

H.C. Wainwright

Emily Bodnar

Price Target

$34 -> $30

AI Analysis

2026-03-13

downgrade

Buy

Reason

H.C. Wainwright analyst Emily Bodnar lowered the firm's price target on Purple Biotech to $30 from $34 and keeps a Buy rating on the shares. The company reported Q4 earnings and provided a corporate update, highlighting recent progress for the company's preclinical CAPTN-3 tri-specific T cell engager programs, the analyst tells investors in a research note. The firm said it expects additional updates regarding progress of the investigational new drug submission and plans for Phase 1 throughout 2026. The firm added that its new price target is based on a discounted cash flow analysis.

Valuation Metrics

The current forward P/E ratio for Purple Biotech Ltd (PPBT.O) is 0.00, compared to its 5-year average forward P/E of -7.15. For a more detailed relative valuation and DCF analysis to assess Purple Biotech Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-7.15

Current PE

0.00

Overvalued PE

15.35

Undervalued PE

-29.66

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

0.85

Current PS

0.00

Overvalued PS

3.29

Undervalued PS

-1.59

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

reverse splits stocks

Intellectia · 1004 candidates

Region: USPrice: <= $5.00Market Cap Category: nano, micro, smallList Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

Zhongchao Inc

75.55K

Steakholder Foods Ltd

1.10M

Visionary Holdings Inc

1.17M

Eason Technology Ltd

1.22M

GD Culture Group Ltd

1.31M

IM Cannabis Corp

1.36M

Whales Holding PPBT

Trading Trends

People Also Watch

Frequently Asked Questions

What is Purple Biotech Ltd (PPBT) stock price today?

The current price of PPBT is 1.55 USD — it has decreased -2.52

What is Purple Biotech Ltd (PPBT)'s business?

Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.

What is the price predicton of PPBT Stock?

Wall Street analysts forecast PPBT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PPBT is34.00 USD with a low forecast of 34.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Purple Biotech Ltd (PPBT)'s revenue for the last quarter?

Purple Biotech Ltd revenue for the last quarter amounts to -2.25M USD, increased 60.10

What is Purple Biotech Ltd (PPBT)'s earnings per share (EPS) for the last quarter?

Purple Biotech Ltd. EPS for the last quarter amounts to -3079000.00 USD, increased 57.74

How many employees does Purple Biotech Ltd (PPBT). have?

Purple Biotech Ltd (PPBT) has 10 emplpoyees as of July 08 2026.

What is Purple Biotech Ltd (PPBT) market cap?

Today PPBT has the market capitalization of 1.48M USD.